Boston Scientific (NYSE:BSX) Given New $49.00 Price Target at BTIG Research

Key Points

• BTIG Research lowered Boston Scientific’s price target to $49 from $56 while maintaining a “buy” rating, implying roughly 16% upside from the stock’s $42.09 price.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $63.77, although several firms have recently reduced targets or moved to neutral/hold ratings.
• Boston Scientific’s latest quarterly revenue exceeded expectations and EPS matched estimates, but an eight-day cybersecurity outage, weaker device demand, margin pressure and a reduced full-year EPS outlook are weighing on the near-term outlook.

Boston Scientific (NYSE:BSX - Get Free Report) had its price objective reduced by equities research analysts at BTIG Research from $56.00 to $49.00 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the medical equipment provider's stock. BTIG Research's price objective points to a potential upside of 16.41% from the stock's current price.

Several other analysts also recently commented on the stock. Barclays upgraded shares of Boston Scientific to a "hold" rating in a report on Wednesday, October 7th. Wall Street Zen downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Sunday, August 2nd. UBS Group dropped their price objective on shares of Boston Scientific from $74.00 to $67.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Raymond James Financial reaffirmed an "outperform" rating and issued a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Citigroup reduced their target price on shares of Boston Scientific from $50.00 to $48.00 and set a "neutral" rating for the company in a research note on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $63.77.

Boston Scientific Stock Performance

BSX stock opened at $42.09 on Thursday. The business's 50-day moving average price is $45.12 and its two-hundred day moving average price is $57.43. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The firm has a market cap of $61.00 billion, a PE ratio of 17.04, a P/E/G ratio of 1.10 and a beta of 0.58. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.73. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.07 billion. During the same period in the prior year, the company earned $0.75 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. As a group, research analysts forecast that Boston Scientific will post 3.21 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger bought 2,100 shares of the company's stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares of the company's stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael F. Mahoney purchased 186,240 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares of the company's stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Corporate insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently made changes to their positions in the stock. Avantax Planning Partners Inc. boosted its holdings in Boston Scientific by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 5,242 shares of the medical equipment provider's stock worth $329,000 after acquiring an additional 201 shares during the last quarter. WPG Advisers LLC grew its stake in shares of Boston Scientific by 11.9% in the 1st quarter. WPG Advisers LLC now owns 1,916 shares of the medical equipment provider's stock worth $120,000 after acquiring an additional 203 shares in the last quarter. Natural Investments LLC raised its holdings in shares of Boston Scientific by 1.3% in the second quarter. Natural Investments LLC now owns 16,067 shares of the medical equipment provider's stock valued at $685,000 after purchasing an additional 206 shares during the last quarter. 180 Wealth Advisors LLC lifted its position in shares of Boston Scientific by 3.6% during the first quarter. 180 Wealth Advisors LLC now owns 6,468 shares of the medical equipment provider's stock valued at $406,000 after purchasing an additional 223 shares in the last quarter. Finally, MGO One Seven LLC lifted its position in shares of Boston Scientific by 1.9% during the third quarter. MGO One Seven LLC now owns 14,061 shares of the medical equipment provider's stock valued at $614,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Third-quarter revenue rose 1.5% to $5.138 billion, exceeding analysts’ $5.07 billion estimate, while adjusted EPS of $0.73 matched expectations. Management also reaffirmed its long-term growth strategy and highlighted progress in clinical programs and FDA clearances. Boston Scientific announces results for third quarter 2026
• Positive Sentiment: Management expects approximately 4% organic revenue growth for full-year 2026 and is targeting a recovery cycle after anticipated 2027 weakness, followed by expansion toward 2030. Recent insider activity also showed purchases rather than sales, including a substantial purchase by CEO Michael Mahoney. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Neutral Sentiment: Needham lowered its price target from $57 to $48 but maintained a Buy rating, while JPMorgan downgraded BSX from Overweight to Neutral and set a $46 target. The revised targets remain above the stock’s recent trading level but reflect reduced confidence in the near-term outlook.
• Negative Sentiment: An eight-day cybersecurity outage reduced third-quarter sales by approximately $150 million and continues to disrupt operations, customer activity, and the recovery timeline. Boston Scientific cut its full-year EPS outlook to $3.16–$3.18 and expects fourth-quarter reported and organic sales to decline 1%–3%. Boston Scientific Crashes As Cybersecurity Attack Weighs On Guide
• Negative Sentiment: Investors are also concerned about contracting margins, weaker heart-device demand, pricing pressure in China, and management’s warning that 2027 could be difficult. GAAP EPS fell to $0.40 from $0.51 a year earlier, and the stock has traded near a four-year low.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.